Trial reportClinical endocrinology2016
Effect of testosterone on hepcidin, ferroportin, ferritin and iron binding capacity in patients with hypogonadotropic hypogonadism and type 2 diabetes.
Trial report in Clinical endocrinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Iron overload disorders in adults: a comprehensive review of gonadal function, reproductive, and sexual health.Human reproduction update · 2026Pooled it
- Markers of Iron Flux during Testosterone-Mediated Erythropoiesis in Older Men with Unexplained or Iron-Deficiency Anemia.The Journal of clinical endocrinology and metabolism · 2020Trial
- Targeting ferroptosis as a therapeutic strategy for hepatotoxicity.Toxicology reports · 2025Review
- Distinct Clusters of Testosterone Levels, Symptoms, and Serum Trace Elements in Young Men: A Cross-Sectional Analysis.Nutrients · 2025Article
- Increased risk of erythrocytosis in men with type 2 diabetes treated with combined sodium-glucose cotransporter-2 inhibitor and testosterone replacement therapy.Journal of endocrinological investigation · 2024Article
- Management of male obesity-related secondary hypogonadism: A clinical update.World journal of experimental medicine · 2024Review
- Hepcidin Reduction during Testosterone Therapy in Men with Type 2 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Study.Biomedicines · 2023Article
- High altitude exposure affects male reproductive parameters: could it also affect the prostate?†.Biology of reproduction · 2022Review
- Review
- Article
- Approach to Interpreting Common Laboratory Pathology Tests in Transgender Individuals.The Journal of clinical endocrinology and metabolism · 2021Review
- Review
- Prevalence of Iron deficiency in Lebanese schoolchildren.European journal of clinical nutrition · 2020Article
- Editorial: Anemia of Old Age.The journal of nutrition, health & aging · 2019Article
- Androgens and Anemia: Current Trends and Future Prospects.Frontiers in endocrinology · 2019Article
- Hepcidin Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Hypogonadotropic Hypogonadism in Men With Diabesity.Diabetes care · 2018Review
- Deletion of ferroportin in murine myeloid cells increases iron accumulation and stimulates osteoclastogenesisThe Journal of biological chemistry · 2018Article
- A Case of Male Osteoporosis: A 37-Year-Old Man with Multiple Vertebral Compression Fractures.Case reports in endocrinology · 2017Article
- Association of serum hepcidin with prostate-specific antigen levels in men from high Andean cities of Peru.International journal of health sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
contextAs the syndrome of hypogonadotropic hypogonadism (HH) is associated with anaemia and the administration of testosterone restores haematocrit to normal, we investigated the potential underlying mechanisms.
designRandomized, double-blind, placebo-controlled trial.
methodsWe measured basal serum concentrations of erythropoietin, iron, iron binding capacity, transferrin (saturated and unsaturated), ferritin and hepcidin and the expression of ferroportin and transferrin receptor (TR) in peripheral blood mononuclear cells (MNC) of 94 men with type 2 diabetes. Forty-four men had HH (defined as subnormal free testosterone along with low or normal LH concentrations) while 50 were eugonadal. Men with HH were randomized to testosterone or placebo treatment every 2 weeks for 15 weeks. Blood samples were collected at baseline, 3 and 15 weeks after starting treatment. Twenty men in testosterone group and 14 men in placebo group completed the study.
resultsHaematocrit levels were lower in men with HH (41·1 ± 3·9% vs 43·8 ± 3·4%, P = 0·001). There were no differences in plasma concentrations of hepcidin, ferritin, erythropoietin, transferrin or iron, or in the expression of ferroportin or TR in MNC among HH and eugonadal men. Haematocrit increased to 45·3 ± 4·5%, hepcidin decreased by 28 ± 7% and erythropoietin increased by 21 ± 7% after testosterone therapy (P < 0·05). There was no significant change in ferritin concentrations, but transferrin concentration increased while transferrin saturation and iron concentrations decreased (P < 0·05). Ferroportin and TR mRNA expression in MNC increased by 70 ± 13% and 43 ± 10%, respectively (P < 0·01), after testosterone therapy.
conclusionsThe increase in haematocrit following testosterone therapy is associated with an increase in erythropoietin, the suppression of hepcidin, and an increase in the expression of ferroportin and TR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.